An economic model evaluated the costs and outcomes of adjunctive clobazam therapy for Lennox-Gastaut syndrome (LGS) compared with adjunctive lamotrigine, rufinamide, and topiramate. Clinical data were used to estimate baseline frequency and the percentage of drop-seizure reductions over 3 months (all comparators) and 2 years (rufinamide). Claims data from a large US health care plan were employed to estimate costs. After 3 months, 21.5% of those receiving clobazam were drop-seizure-free. Over a 3-month horizon, clobazam was more effective and less expensive than comparators, with the assumption that N0.77% of drop seizures required medical care. Below this threshold, topiramate was less costly than clobazam. With the base-case assumption that 2.3% of drop seizures were medically attended, costs for patients receiving clobazam totaled $30,147 versus $34,223-$35,378 for comparators. Clobazam was more efficacious and less costly than rufinamide over a 2-year horizon. The percentage of medically attended drop seizures was a driver of results. Clobazam treatment may be cost-saving.
Introduction
Lennox-Gastaut syndrome (LGS) is a debilitating form of childhood epilepsy. The onset of LGS typically occurs between ages 1 and 7, and LGS is estimated to account for up to 10% of childhood epilepsies [1, 2] . Though no specific characteristics are diagnostic of LGS, it is associated with frequent tonic or atonic falls ("drop attacks") and cognitive impairment [3] . Patients with LGS have an increased risk of mortality [4, 5] , and nearly half of all patients with LGS experience sudden drop attacks, which can lead to serious physical injury [1] .
Lennox-Gastaut syndrome has considerable economic impact. Seizures attributed to LGS are often refractory to treatment and, therefore, increase the likelihood of patient hospitalization. A resource utilization study found that seizures accounted for 16.9% of hospital admissions in 2006 [6] , with an estimated annual cost per patient of $4,553 [7] . A survey-based analysis found that annual US medical costs were notably greater for children with epilepsy than for children without epilepsy ($6,379 vs. $1,976, respectively, adjusted for 2004 prices) [8] . In another survey-based analysis of adult patients, the annual cost of epilepsy was projected to be $12.5 billion, including both direct costs (e.g., medical services, diagnostic procedures, emergency room visits) and indirect costs (e.g., lost wages for caregivers), adjusted to 1995 prices [9] . Approximately 80% of these costs were attributed to patients who had intractable seizures.
Four antiepileptic drugs (AEDs: felbamate, lamotrigine, topiramate, and rufinamide) had been approved by the US Food and Drug Administration (FDA) for the treatment of LGS. Clobazam (Onfi) became the fifth when it was approved in October 2011 as an adjunctive treatment for seizures associated with LGS for patients 2 years and older. Although information about the economic profile of AEDs for the treatment of LGS is limited, recent analyses have reported the cost effectiveness of rufinamide in the United Kingdom. Adjunctive therapy with rufinamide was more costly than topiramate and lamotrigine but resulted in reduced frequency of total seizures and drop attacks [10] and greater quality-adjusted life-years (QALYs) [11] . Rufinamide was cost-effective at a £30,000 per QALY gained threshold (e.g., compared with topiramate but not lamotrigine). With the approval of clobazam as an adjunctive treatment for LGS in the United States, the current analysis was conducted to estimate the short-and long-term cost effectiveness of clobazam as adjunctive therapy for LGS from a US payer perspective.
Methods
A trial-based economic model was developed to evaluate the cost effectiveness and outcomes of clobazam versus competitor AEDs in the treatment of LGS over 3-month and 2-year time frames. E-mail address: karen.clements@optum.com (K.M. Clements).
Patient population
The model patient population comprised individuals with LGS with characteristics similar to patients who had enrolled in the pivotal study OV-1012 (also known as the CONTAIN trial) [12] . Key patient characteristics included the following: 1) an LGS diagnosis, 2) 2 to 54 years of age with LGS onset before 11 years of age, 3) ≥2 drop seizures per week, and 4) treatment with 1-3 concomitant AEDs.
Model overview and structure
At model initiation, patients were assumed to have had the same average number of drop seizures per month as patients in clobazam clinical trials at baseline, depending on the model time horizon: 128 drop seizures/month for the 3-month horizon (CONTAIN) [12] and 132 drop seizures/month for the 2-year horizon (OV-1004 clobazam open-label extension [OLE] trial) [13] . Model assumptions were that patients had the midpoint number of drop seizures in their seizure-reduction categories and that change in drop seizures was linear between time points. The average cost per drop seizure was multiplied by the number of drop seizures occurring each month. Utility values were assigned based on drop-seizure reduction category each month. The model assumed a target clobazam dosage of 1.0 mg/kg/day for both the 3-month and 2-year time frame analyses.
After short-term treatment in the 3-month model, patients were classified by their percentage decreases in drop-seizure frequency from baseline (i.e., 128/month): 0%-b 50%, 50%-b100%, and 100% (seizurefree). Model comparators for the 3-month analysis included rufinamide (maximum dosage of 45 mg/kg/day), topiramate (target dosage of 6 mg/kg/day), and lamotrigine (maximum dosage of 5 mg/kg/day for patients also receiving valproate; 15 mg/kg/day for patients not receiving valproate). Since no head-to-head comparison trials of these AEDs have been reported, efficacy estimates were adjusted for study differences using an indirect comparison of relative efficacy versus a common comparator (Table 1) [12, [14] [15] [16] . Definitions of drop seizures differed slightly between trials (e.g., rufinamide and topiramate trials: drop seizures included tonic-atonic seizures; lamotrigine and clobazam trials: drop seizures included atonic, tonic, and myoclonic seizures that resulted in falls).
After long-term treatment in the 2-year model, patients were classified by their percentage decreases in drop-seizure frequency from baseline (i.e., 132/month): 0%-b 50%, 50%-b75%, 75%-b 100%, and 100% (seizure-free). Over 2 years, 17.9% of patients receiving clobazam and 57.3% of patients receiving rufinamide discontinued treatment. Patients who discontinued at each time point were assumed to have returned to their baseline drop-seizure rates. The model comparator for the 2-year analysis was rufinamide (maximum dosage of 45 mg/kg/day).
Efficacy estimates for the decrease in drop seizures over 24 months were derived from open-label studies of clobazam [13] and rufinamide [17] (Table 2 ). It should be noted that the percentage of rufinamide patients in each drop-seizure reduction category was reported at 36 months only. Interim efficacy outcomes were calculated using the fraction of the 36-month median reduction that had been achieved at each 3-month time point. The fractions of the final percentage reduction at each time point were then multiplied by the percentage of patients in each drop-seizure reduction category (50%-b 75%, 75%-b 100%, and 100%) at the end of the trial to obtain the number of patients in each reduction category every 3 months.
Cost parameters
Mean health care costs for medically attended seizures were identified from a retrospective claims database analysis of patients with LGS via administrative claims data from a large managed health care plan (January 2007 to September 2010). An algorithm, developed in consultation with a pediatric neurologist (Dr. Deborah Lee, Lundbeck LLC), was used to identify patients with LGS in the claims database and the cost of seizure-attributable events (see Appendix A), which was estimated to be $5,501 in 2013 US dollars [18] . Based on estimates from the literature and the claims database analysis [10, 18] , it was assumed that 0.5% of drop attacks resulted in hospitalization, representing 21.5% of all seizures necessitating any medical costs (e.g., inpatient, outpatient, emergency room services). However, this analysis also sought to consider drop attacks treated in the clinical setting, as well as those treated in the hospital setting. Therefore, with the algorithm and these assumptions, 2.3% of drop seizures were assumed to have been medically attended.
Daily drug costs (based on 2013 prices) were calculated by applying the average dosages received in clinical trials (titration and maintenance periods) -$22.41 for clobazam, $31.69 for rufinamide, $0.12 for topiramate, and $0.12 for lamotrigine -to the 2013 wholesale acquisition costs (WACs) [19] .
Utility weights
For estimation of the number of QALYs associated with each treatment, utility weights (a value that quantifies health-related quality of life in each health state, ranging from 0 [death] to 1 [perfect health]) were assigned to the drop-seizure reduction categories used in the model. Utility estimates were obtained from a published study of cost effectiveness of rufinamide in the treatment of LGS (Table 3 ) [20] . The study did not report the utility weight associated with 100% reduction. As a conservative estimate, the 100% reduction group was assumed to have had the same utility weight as the 75%-b100% seizure-reduction group. a Indirect comparisons were used to adjust estimates. 
Adverse events
Costs and disutility of adverse events were not considered in the model. The most common adverse effects reported during the clinical trials (e.g., somnolence, vomiting, diarrhea, and fever) were considered to be brief and not associated with a sustained decrease in quality of life or medical costs.
Model outputs and analyses
The model produced estimates of the total number of QALYs, number of drop seizures, the percentage of patients who achieved dropseizure freedom, and total costs. To calculate quality-adjusted lifeyears, the percentage of the sample in each drop-seizure reduction category each month was multiplied by the utility value associated with the category and summed over the model horizon.
Cost-effectiveness analysis
The cost effectiveness of clobazam was measured using incremental cost-effectiveness ratios (ICERs). These ICERs were estimated by rankordering treatment strategies by increasing cost and comparing more costly strategies with less costly strategies by dividing the additional cost by the additional benefit. A more costly strategy that provided no additional benefit was said to be "dominated." Cost effectiveness was expressed as cost per QALY gained, cost per drop seizure avoided, and cost per drop-seizure-free patient.
Deterministic sensitivity analyses
Deterministic (i.e., one-way) sensitivity analyses were performed to assess the sensitivity of the cost-effectiveness analysis results to changes in the values of input parameters. To perform these analyses, we varied each parameter one at a time over the 95% confidence interval of the base-case values. When 95% confidence intervals were not available, parameters were varied by ± 25% of the base-case values.
Probabilistic sensitivity analysis
A second-order probabilistic Monte Carlo sensitivity analysis assessed uncertainty around the following base-case parameter values: transition probabilities, treatment-related adverse events, utilities, and treatment costs. Each parameter was characterized by probability distributions around their midpoint estimates. A random number generator was used to "draw" values from each distribution to generate estimates of cost effectiveness for each treatment strategy. This process was repeated 1000 times, and the incremental results are presented graphically. The Monte Carlo simulation estimated the likelihood that clobazam was the dominant strategy.
Additional sensitivity and alternative scenario analyses
When underlying model assumptions were uncertain, additional sensitivity and alternative scenario analyses were conducted to test the impact of alternative plausible assumptions. Analysis 1 presented model results for a range of values for the assumption of the percentage of seizures requiring medical attention. First, we calculated the parameter value at which the clobazam regimen was no longer the dominant regimen. Next, for all values below the threshold, we calculated ICERs comparing clobazam to the less costly regimen. In Analysis 2, an alternative scenario was performed in which discontinuers were assumed to have maintained seizure control and retained their average percentage decreases in drop seizures for the remaining horizon in the 2-year model.
Results

Base case: 3-month model
The adjusted percentage decreases of drop seizures per patient over 3 months for clobazam, rufinamide, topiramate, and lamotrigine were 64%, 51%, 46%, and 44%, respectively. The mean numbers of drop seizures per patient over 3 months are shown in Fig. 1A . Per-patient drop-seizure costs were 93.3%, 91.9%, 99.9%, and 99.9% of the total treatment costs for the clobazam, rufinamide, topiramate, and lamotrigine groups, respectively ( Table 4 ). The model suggests that, over 3 months, patients who received clobazam experienced fewer drop-seizure events than those who received AED comparators (clobazam, 220; rufinamide, 254; topiramate, 267; lamotrigine, 273), resulting in greater qualityadjusted life-years gained. Moreover, 21.5% of patients who received clobazam were free of drop seizures, compared with b5% for the AED comparators. Clobazam dominated all comparators (i.e., it was less expensive and more effective) in QALYs gained, decreases in dropseizure events, and percentage of patients who had attained dropseizure freedom over the 3-month horizon (Table 5 ).
Base case: 2-year model
Over 2 years, patients receiving clobazam had a 53% reduction in drop seizures, compared with a 33% reduction for patients receiving rufinamide (Fig. 1B) . The total per-patient drug and drop-seizure costs were $177,068 for patients receiving clobazam and $265,814 for patients receiving rufinamide ( drop-seizure events avoided, and percentage of drop-seizure-free patients over a 2-year horizon.
Deterministic sensitivity analysis
When model parameters were varied one at a time through a range of values, clobazam remained the dominant strategy (i.e., more effective and less expensive) versus comparators in all scenarios over the 3-month and 2-year time horizons.
Probabilistic sensitivity analysis
Incremental costs and outcomes of clobazam compared with rufinamide over the 3-month and 2-year time horizons showed that clobazam was dominant in 100% of iterations ( Figs. 2A and B) . (Table 6 ). Over the 2-year time horizon, clobazam was dominant for all values of the percentage of seizures medically attended.
Scenario-2 analysis (clobazam vs. rufinamide)
With the assumption that discontinuers retained their average percentage drop-seizure decreases for the remaining horizon over the 2-year time frame, clobazam dominated rufinamide as the latter was both more expensive and less effective (Table 7) .
Discussion
In this study, costs and outcomes associated with adjunctive clobazam treatment in patients with LGS were compared with adjunctive treatment with rufinamide, topiramate, and lamotrigine over a 3-month horizon and with rufinamide over a 2-year horizon. The time horizons were based on the availability of trial-based, short-and long-term data. In base-case analyses, clobazam was more efficacious and less expensive (i.e., greater drop-seizure reduction and number of QALYs gained) than the comparator AEDs over both time horizons. Results from deterministic sensitivity analyses revealed that the base-case parameter estimates were robust to reasonable variations across the 95% confidence interval range. Clobazam was also the dominant treatment strategy in 100% of the iterations of the probabilistic sensitivity analysis. Overall, patients treated with comparators had greater medical costs than patients treated with clobazam, and this difference was driven by reductions in medically attended drop seizures in patients treated with clobazam.
The estimate for the percentage of medically attended drop seizures (2.3%) could not be identified directly from the literature or database analysis but was derived from the results of a survey of physicians in the United Kingdom of the percentage of seizures that required hospitalization [10] and a US-based retrospective claims database analysis [18] . The survey encompassed all types of epilepsy and was not targeted solely or specifically at a catastrophic epilepsy syndrome such as LGS. Unlike the Verdian et al. analysis, which considered only seizures attended in the hospital setting, we considered a percentage that would reflect seizures treated in both the hospital and clinical settings. The claims analysis was also used to estimate medical costs associated with each seizure [10, 18] . Interpretation of the claims analysis is subject to the following limitations: 1) An ICD-9 code specific to the LGS form of epilepsy does not exist, therefore an algorithm was used to identify the patient population (algorithm has not been validated); 2) The study was conducted in a managed care population and may not be indicative of patients in a non-managed care setting; 3) Although claims are excellent for understanding patterns of health care utilization, they are subject to possible coding errors, such as coding for the purpose of "ruling out" rather than actual disease coding and undercoding; and 4) Certain clinical and disease-specific parameters that could have an effect on study outcomes are not readily available in claims data. Given the uncertainty in the estimate of medically attended drop seizures, we performed additional sensitivity analyses to evaluate the results, following a range of assumptions. Results demonstrated that over a 3-month horizon, clobazam was still the dominant regimen at all values greater than 0.77%. Moreover, clobazam remained dominant when compared with rufinamide in the 2-year model at all values. In addition, our alternative scenario and sensitivity analyses were broad enough to encompass the percentage of medically attenuated seizures reported in the hospital setting in the Verdian et al. analysis (0.5%) [10] .
When data were not available, the following assumptions in the base-case analysis were used to provide estimates. Patients were assumed to have had the midpoint number of drop seizures in each drop-seizure category and a linear change in drop seizures during each 3-month interval for which data were reported. In addition, the percentage of patients achieving each drop-seizure category at each 3-month interval was not reported in the rufinamide open-label study [17] , and, therefore, the percentage of patients reaching each drop-seizure category was assumed to have been proportional to the median seizure reduction at that time point.
In the base-case analysis, it was also assumed that patients who discontinued treatment returned to their baseline drop-seizure rates. A second alternative analysis assumed that patients who had discontinued treatment maintained seizure control. The results from the second alternative analysis did not alter the conclusion that clobazam was the dominant treatment.
Publications describing cost-effectiveness evaluations of AEDs in a patient population with LGS are limited [10, 11, 21] . In the only publication presenting a cost-utility analysis, Verdian et al. estimated that rufinamide costs £20,538 and £154,831 per QALY gained compared with topiramate and lamotrigine, respectively, over 3 years in patients with LGS in the UK [11] . Our study estimated that clobazam was dominant compared with topiramate and lamotrigine, as well as rufinamide. The differences between our study and the Verdian study were as follows: 1) The lack of published long-term efficacy data for topiramate and lamotrigine limited our study to a 3-month horizon to evaluate cost effectiveness of clobazam relative to all AED comparators. If the long-term efficacy of topiramate and lamotrigine followed the same pattern as clobazam and rufinamide, clobazam would have remained dominant relative to these two drugs over the long term; and 2) In their study, Verdian et al. included only hospital costs, estimating that 0.5% of drop seizures led to hospitalization, whereas our study included the costs of hospitalization and outpatient treatment. Although we estimated a greater cost per medically attended drop seizure, clobazam dominated rufinamide in the 2-year horizon.
Development of tolerance is a concern with the use of all AEDs, especially the long-term use of benzodiazepines. We could not account for tolerance rates of topiramate, lamotrigine, and rufinamide. Some of the latest reports for clobazam do not necessarily agree. An independent, retrospective chart review of 46 patients with LGS at the pediatric neurology department of Asan Medical Center in Seoul, Korea (2000-2009), reported tolerance for 12 of 25 patients (48%) [22] . However, several incongruences were reported in this and other analyses: "Despite the development of tolerance, once complete remission had been maintained, a significant proportion of patients were found to remain seizure-free" [22, 23] . Well-controlled data from 188 patients who completed a 6-year open-label extension trial [24] found limited development of tolerance, as suggested by sustained responses over time; stable mean modal clobazam dosages over time; a substantial percentage (70%) of patients remaining in treatment through study completion, with few discontinuing because of lack of efficacy; and some patients being able to reduce their concomitant AED therapies. Therefore, it is difficult to speculate on the roles, if any, of tolerance in these analyses.
In summary, this cost-effectiveness analysis suggests that treatment with clobazam over the short-and long-term horizon is both less costly and results in better efficacy outcomes than lamotrigine, rufinamide, and topiramate. The results suggest that treatment with clobazam leads to lower overall health care costs through a reduction in the number of medically attended drop seizures, especially in the long term. Nevertheless, long-term data from patients prescribed clobazam in the clinical setting will be critical to determining true cost effectiveness.
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